Malignancy outcomes in patients with rheumatoid arthritis treated with abatacept and other disease-modifying antirheumatic drugs: Results from a 10-year international post-marketing study
Authors:
Open Access
- 30 June 2023
- journal article
- research article
- Published by Elsevier in Seminars in Arthritis and Rheumatism
- Vol. 64, 152240
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Co Summit
- Bristol-Myers Squibb
This publication has 34 references indexed in Scilit:
- Safety of Abatacept Administered Intravenously in Treatment of Rheumatoid Arthritis: Integrated Analyses of up to 8 Years of Treatment from the Abatacept Clinical Trial ProgramThe Journal of Rheumatology, 2013
- Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trialAnnals of the Rheumatic Diseases, 2011
- Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)Annals of the Rheumatic Diseases, 2010
- Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBITArthritis Research & Therapy, 2010
- The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trialAnnals of the Rheumatic Diseases, 2009
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals of the Rheumatic Diseases, 2008
- A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritisArthritis Research & Therapy, 2008
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals of the Rheumatic Diseases, 2007
- Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled studyArthritis & Rheumatism, 2006
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986